[go: up one dir, main page]

PE20161242A1 - Formulaciones de lipidos para la administracion de arn mensajero - Google Patents

Formulaciones de lipidos para la administracion de arn mensajero

Info

Publication number
PE20161242A1
PE20161242A1 PE2016000532A PE2016000532A PE20161242A1 PE 20161242 A1 PE20161242 A1 PE 20161242A1 PE 2016000532 A PE2016000532 A PE 2016000532A PE 2016000532 A PE2016000532 A PE 2016000532A PE 20161242 A1 PE20161242 A1 PE 20161242A1
Authority
PE
Peru
Prior art keywords
cholesterol
administration
lipids
messenger rna
lipid formulations
Prior art date
Application number
PE2016000532A
Other languages
English (en)
Inventor
Daniel Anderson
Michael Heartlein
Yizhou Dong
Frank Derosa
Original Assignee
Massachusetts Inst Technology
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51844901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Inst Technology, Shire Human Genetic Therapies filed Critical Massachusetts Inst Technology
Publication of PE20161242A1 publication Critical patent/PE20161242A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN ARNm QUE CODIFICA UNA PROTEINA TAL COMO ARGININOSUCCINATO SINTETASA (ASS1), FACTOR IX, FENILALANINA HIDROXILASA, ENTRE OTROS, EL CUAL SE ENCUENTRA ENCAPSULADO DENTRO DE UN LIPOSOMA QUE COMPRENDE i) UN LIPIDO CATIONICO DE FORMULA I-C DONDE p, R2, R6 Y R7 SON TAL COMO SE DEFINEN EN LA DESCRIPCION, SIENDO PREFERIDO EL LIPIDO CKK-E12; ii) LIPIDOS NO CATIONICOS TAL COMO 1,2-DIOLEIL-SN-GLICERO-3-FOSFOETANOLAMINA (DOPE), 1,2-DIPALMITOIL-SN-GLICERO-3-FOSFOCOLINA (DPPC), ENTRE OTROS; iii) LIPIDOS A BASE DE COLESTEROL TAL COMO COLESTEROL O COLESTEROL PEGILADO; Y iv) LIPIDOS MODIFICADOS POR PEG TAL COMO DMG-PEG2K; SIENDO UNA COMBINACION PREFERIDA DE LIPIDOS: CKK-E12, DOPE, COLESTEROL Y DMG-PEG2K. TAMBIEN SE REFIERE A UN METODO DE ADMINISTRACION DE DICHA COMPOSICION
PE2016000532A 2013-10-22 2014-10-22 Formulaciones de lipidos para la administracion de arn mensajero PE20161242A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894299P 2013-10-22 2013-10-22
US201461953516P 2014-03-14 2014-03-14

Publications (1)

Publication Number Publication Date
PE20161242A1 true PE20161242A1 (es) 2016-12-11

Family

ID=51844901

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000532A PE20161242A1 (es) 2013-10-22 2014-10-22 Formulaciones de lipidos para la administracion de arn mensajero

Country Status (16)

Country Link
US (6) US9629804B2 (es)
EP (2) EP3060257B1 (es)
JP (6) JP6525435B2 (es)
KR (2) KR101988552B1 (es)
CN (3) CN112656954A (es)
AU (4) AU2014340155B2 (es)
BR (1) BR112016009077A2 (es)
CL (1) CL2016000957A1 (es)
EA (1) EA201690576A1 (es)
ES (2) ES3032935T3 (es)
IL (1) IL245030A0 (es)
MX (1) MX2016005238A (es)
NZ (1) NZ718817A (es)
PE (1) PE20161242A1 (es)
SG (1) SG11201602943PA (es)
WO (1) WO2015061467A1 (es)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2012075040A2 (en) * 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
BR112013031553A2 (pt) * 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
ES2663360T3 (es) 2011-06-08 2018-04-12 Translate Bio, Inc. Lípidos escindibles
CN113149869A (zh) 2011-10-27 2021-07-23 麻省理工学院 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015061467A1 (en) * 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
MX381303B (es) * 2013-10-22 2025-03-12 Shire Human Genetic Therapies Composición que comprende un ácido ribonucleico mensajero que codifica argininosuccinato sintetasa para usarse en el tratamiento de la deficiencia de argininosuccinato sintetasa.
EP3122878B1 (en) * 2014-03-24 2018-10-24 Translate Bio, Inc. Mrna therapy for the treatment of ocular diseases
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN114642735A (zh) 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
HUE062274T2 (hu) * 2015-06-19 2023-10-28 Massachusetts Inst Technology Alkenil-szubsztituált 2,5-piperazindionok és alkalmazásuk hatóanyag alanyba vagy sejtbe történõ célbajuttatására szolgáló készítményekben
CA3003090A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CN105200158B (zh) * 2015-11-06 2018-09-21 中国医学科学院北京协和医院 Ass1甲基化检测在骨性关节炎诊断中的应用
CA3014498A1 (en) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
KR20220159479A (ko) 2016-05-18 2022-12-02 모더나티엑스, 인크. 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
WO2017201347A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2017205566A1 (en) * 2016-05-27 2017-11-30 Preceres Inc. Oxidized aminolipidoids and uses thereof
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
AU2017357748B2 (en) 2016-11-10 2023-11-09 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mRNA
AU2017361521B2 (en) 2016-11-21 2020-08-27 Bruker Spatial Biology, Inc. Chemical compositions and methods of using same
ES2912270T3 (es) * 2016-11-23 2022-05-25 Mayo Found Medical Education & Res Transporte de productos biológicos por medio de partículas
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
IL285053B (en) 2017-01-23 2022-07-01 Regeneron Pharma Variants of hsd17b13 and their uses
US10975369B2 (en) 2017-02-27 2021-04-13 Translate Bio, Inc. Methods for purification of messenger RNA
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
ES2899323T3 (es) 2017-02-27 2022-03-10 Translate Bio Inc Métodos de purificación de ARN mensajero
SG11201909453RA (en) 2017-04-11 2019-11-28 Regeneron Pharma Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
US12350368B2 (en) 2017-04-14 2025-07-08 The Broad Institute, Inc. Delivery of large payloads
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
EP3658672A1 (en) * 2017-07-24 2020-06-03 Modernatx, Inc. Modified mrna encoding a glucose-6-phosphatase and uses thereof
EP4234719B1 (en) 2017-10-11 2025-11-26 Regeneron Pharmaceuticals, Inc. Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
WO2019135816A2 (en) 2017-10-23 2019-07-11 The Broad Institute, Inc. Novel nucleic acid modifiers
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
JP7423522B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
MA50801A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
US12359201B2 (en) 2018-03-21 2025-07-15 Regeneron Pharmaceuticals, Inc. 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
CA3099909A1 (en) 2018-05-14 2019-11-21 Nanostring Technologies, Inc. Chemical compositions and methods of using same
CA3097912A1 (en) * 2018-05-15 2019-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger rna
US20200016274A1 (en) 2018-05-30 2020-01-16 Translate Bio, Inc. Messenger rna vaccines and uses thereof
CA3109138A1 (en) * 2018-08-14 2020-02-20 Loxegen Holdings Pty Ltd Nanoparticles for transfection
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
EP3843709A1 (en) * 2018-08-29 2021-07-07 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US20220054610A1 (en) * 2018-09-12 2022-02-24 University Of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
EP3861108A1 (en) 2018-10-04 2021-08-11 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
ES2982542T3 (es) 2018-10-09 2024-10-16 Univ British Columbia Composiciones y sistemas que comprenden vesículas competentes para la transfección sin solventes orgánicos ni detergentes y métodos relacionados con los mismos
KR20210089648A (ko) 2018-11-08 2021-07-16 트랜슬레이트 바이오 인코포레이티드 메신저 rna 정제를 위한 방법 및 조성물
US20220096612A1 (en) 2018-11-12 2022-03-31 Translatebioinc Methods for inducing immune tolerance
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
EP4491229A3 (en) 2019-02-08 2025-05-14 CureVac SE Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CN110302373A (zh) * 2019-07-01 2019-10-08 大连民族大学 利用跨膜区定向排列病毒包膜蛋白疫苗及其制备方法
CN114206906B (zh) * 2019-07-10 2024-02-20 香港大学 Peg化的合成kl4肽、其组合物和方法
CN114423869A (zh) 2019-07-19 2022-04-29 旗舰先锋创新Vi有限责任公司 重组酶组合物和使用方法
CN114401748A (zh) * 2019-07-23 2022-04-26 川斯勒佰尔公司 负载mRNA的脂质纳米颗粒的稳定组合物及制备方法
IL290078B2 (en) 2019-07-30 2025-09-01 Translate Bio Inc Treatment of cystic fibrosis by administering mRNA encoding CFTR in the form of a fine spray
BR112022001947A2 (pt) 2019-08-14 2022-09-20 Curevac Ag Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
WO2021041267A1 (en) 2019-08-23 2021-03-04 New England Biolabs, Inc. Enzymatic rna capping method
KR20220046693A (ko) 2019-08-23 2022-04-14 뉴 잉글랜드 바이오랩스, 인크 효소학적 rna 캡핑 방법
US12398173B2 (en) 2019-08-23 2025-08-26 New England Biolabs, Inc. Enzymatic RNA capping method
KR102164218B1 (ko) * 2019-09-24 2020-10-12 코스맥스 주식회사 피부 흡수 증진을 위한 다중층 양이온성 리포좀 및 이의 제조방법
US20220370351A1 (en) * 2019-10-04 2022-11-24 National University Corporation Hokkaido University Three-dimensional flow path structure body and nanoparticle production method using same
US12076438B2 (en) 2019-10-09 2024-09-03 Translate Bio, Inc. Compositions, methods and uses of messenger RNA
IL294073A (en) * 2019-12-20 2022-08-01 Translate Bio Inc Rectal administration of messenger rna
KR102198736B1 (ko) 2020-01-15 2021-01-05 이화여자대학교 산학협력단 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도
DE112021000012C9 (de) 2020-02-04 2025-02-06 CureVac SE Coronavirus-Vakzine
AU2021226578A1 (en) 2020-02-25 2022-10-20 Translate Bio, Inc. Improved processes of preparing mRNA-loaded lipid nanoparticles
CA3172591A1 (en) 2020-03-24 2021-09-30 Douglas Anthony KERR Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
MX2022011805A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
EP4125816A4 (en) * 2020-04-01 2024-01-10 University of Cincinnati MATERIALS AND METHODS FOR IMMUNOSUPRESSIVE TUMOR MICRO-TARGETED CANCER THERAPY
CA3177006A1 (en) * 2020-04-27 2022-10-26 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
US20230181619A1 (en) * 2020-05-07 2023-06-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
US20230193311A1 (en) 2020-05-20 2023-06-22 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
MX2022014653A (es) 2020-05-20 2023-02-16 Flagship Pioneering Innovations Vi Llc Composiciones de antigeno de coronavirus y sus usos.
IL298539A (en) 2020-05-29 2023-01-01 Flagship Pioneering Innovations Vi Llc Trem compositions and methods relating thereto
CA3182026A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
BR112022024248A2 (pt) 2020-05-29 2023-10-10 CureVac SE Vacinas de combinação à base de ácido nucleico
CN111658782A (zh) * 2020-06-10 2020-09-15 深圳近邻生物科技有限公司 mRNA疫苗递送载体及制备方法、mRNA疫苗及制备方法
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
US11788074B2 (en) 2020-06-23 2023-10-17 New England Biolabs, Inc. Vaccinia capping enzyme compositions and methods
CN111635937B (zh) * 2020-06-29 2021-10-08 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
JP2023542492A (ja) 2020-09-03 2023-10-10 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 免疫原性組成物及びその使用
WO2022066916A1 (en) * 2020-09-23 2022-03-31 Translate Bio, Inc. Piperazine-based cationic lipids
CA3195123A1 (en) 2020-10-14 2022-04-21 Michael Daro BUSCHMANN Methods of lipid nanoparticle manufacture and compostions derived therefrom
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
JP2023548587A (ja) * 2020-11-09 2023-11-17 トランスレイト バイオ， インコーポレイテッド コドン最適化したｍＲＮＡの送達のための改善された組成物
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
WO2022155195A1 (en) * 2021-01-12 2022-07-21 Peranteau William Ionizable lipid nanoparticles for in utero mrna delivery
WO2022164428A1 (en) 2021-01-27 2022-08-04 New England Biolabs, Inc. Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US11028379B1 (en) 2021-01-27 2021-06-08 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
AU2022232410A1 (en) * 2021-03-08 2023-10-05 Eyegene Inc. Composition for in vivo delivery of rna and preparation method therefor
IL305782A (en) 2021-03-22 2023-11-01 Recode Therapeutics Inc Compositions and methods for targeted delivery to cells
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
KR20240012370A (ko) 2021-04-20 2024-01-29 안자리움 바이오사이언시스 아게 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
US20250082640A1 (en) * 2021-04-23 2025-03-13 University Of Cincinnati Therapeutics for Hyponatremia and Polycystic Kidney Disease
CN117881786A (zh) 2021-04-27 2024-04-12 世代生物公司 表达治疗性抗体的非病毒dna载体及其用途
EP4329884A1 (en) 2021-04-27 2024-03-06 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
AU2022273530A1 (en) 2021-05-12 2023-11-23 Massachusetts Institute Of Technology Modified mrna, modified non-coding rna, and uses thereof
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
CA3229889A1 (en) 2021-09-03 2023-03-09 Glaxosmithkline Biologicals Sa Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023044006A1 (en) 2021-09-17 2023-03-23 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
US20240316216A1 (en) 2021-10-06 2024-09-26 Massachusetts Institute Of Technology Lipid nanoparticles for drug delivery to microglia in the brain
KR20240126857A (ko) 2021-10-18 2024-08-21 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CA3236235A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
CA3239266A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
US20240401024A1 (en) 2021-12-17 2024-12-05 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
CN118679254A (zh) 2021-12-22 2024-09-20 旗舰创业创新六公司 用于纯化多核糖核苷酸的组合物和方法
CA3241026A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
EP4463475A2 (en) 2022-01-14 2024-11-20 Anjarium Biosciences AG Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
CA3242744A1 (en) 2022-01-27 2023-08-03 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for the administration of herpes simplex virus antigens and associated methods
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4490285A1 (en) 2022-03-11 2025-01-15 New England Biolabs, Inc. Immobilized enzyme compositions and methods
JP2025509607A (ja) 2022-03-14 2025-04-11 ジェネレーション バイオ カンパニー 異種プライムブーストワクチン組成物及び使用の方法
CN119072464A (zh) 2022-03-25 2024-12-03 赛欧生物医药股份有限公司 新型可电离脂质和脂质纳米颗粒以及其使用方法
EP4504252A2 (en) 2022-04-08 2025-02-12 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
CA3257006A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
EP4522753A2 (en) 2022-05-13 2025-03-19 Flagship Pioneering Innovations VII, LLC Double stranded dna compositions and related methods
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
AU2023283348A1 (en) 2022-06-07 2025-01-09 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
FR3136367A1 (fr) * 2022-06-09 2023-12-15 Damien SULEIMAN Compositions et méthodes concernant des molécules d’ARN messager codant le facteur V encapsulées dans des nanoparticules lipidiques
WO2023242817A2 (en) 2022-06-18 2023-12-21 Glaxosmithkline Biologicals Sa Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
IL318711A (en) 2022-08-01 2025-03-01 Flagship Pioneering Innovations Vii Llc Immune modulator proteins and related methods
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
CN120239693A (zh) 2022-08-31 2025-07-01 赛欧生物医药股份有限公司 新型可电离脂质和脂质纳米颗粒以及其使用方法
KR102785258B1 (ko) * 2022-09-07 2025-03-26 아이진 주식회사 변형핵산 함유 mRNA의 체내 전달용 조성물
WO2024054020A1 (ko) * 2022-09-07 2024-03-14 아이진 주식회사 변형핵산 함유 mrna의 체내 전달용 조성물
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
EP4590330A1 (en) 2022-09-23 2025-07-30 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
KR20250075664A (ko) 2022-09-26 2025-05-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 바이러스 백신
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
KR20250099195A (ko) 2022-10-31 2025-07-01 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
CN120435298A (zh) 2022-11-08 2025-08-05 旗舰创业创新第六有限责任公司 用于产生环状多核糖核苷酸的组合物和方法
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
EP4615517A1 (en) 2022-11-08 2025-09-17 Orna Therapeutics, Inc. Circular rna compositions
WO2024119103A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
CN120615013A (zh) 2022-12-01 2025-09-09 世代生物公司 用于细胞靶向的隐形脂质纳米颗粒组合物
JP2025540076A (ja) 2022-12-01 2025-12-11 ジェネレーション バイオ カンパニー 核酸、イオン化可能な脂質、ステロール、脂質アンカーポリマー、及びヘルパー脂質を含む脂質ナノ粒子、それらの使用
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
EP4636090A1 (en) * 2022-12-16 2025-10-22 Shenzhen Shenxin Biotechnology Co., Ltd. Utr for improving translation efficiency and/or stability of rna molecule and use thereof
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
EP4654996A1 (en) 2023-01-27 2025-12-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein c, glycoprotein d, and glycoprotein e antigens and related methods
CN116047082B (zh) * 2023-01-31 2023-09-15 江苏品升医学科技有限公司 一种fgl1蛋白用于制备诊断慢性肾脏病的试剂盒的用途
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節組合物及相關方法
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024173836A2 (en) 2023-02-17 2024-08-22 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
TW202438089A (zh) 2023-02-17 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 包含經修飾的尿嘧啶的ｄｎａ組成物
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
CN121127594A (zh) 2023-03-15 2025-12-12 旗舰创业创新第六有限责任公司 包含多核糖核苷酸的组合物及其用途
CN121358494A (zh) 2023-03-15 2026-01-16 旗舰创业创新第六有限责任公司 免疫原性组合物及其用途
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024216191A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
KR20250171373A (ko) 2023-04-12 2025-12-08 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 미스센스 돌연변이 교정용 trem
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
AU2024260120A1 (en) 2023-04-27 2025-11-06 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
AU2024265158A1 (en) 2023-05-03 2025-11-06 BioNTech SE Optimized csp variants and related methods
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
AU2024301077A1 (en) 2023-07-21 2026-01-08 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024337A1 (en) 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
US20250092426A1 (en) 2023-07-25 2025-03-20 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
TW202540154A (zh) 2023-09-11 2025-10-16 德商拜恩技術股份公司 用於遞送腸促胰島素劑之ｒｎａ組合物
WO2025059500A1 (en) 2023-09-14 2025-03-20 New England Biolabs, Inc. Rna polymerases
WO2025064475A2 (en) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
US20250177432A1 (en) * 2023-12-04 2025-06-05 Wuhan Houxian Biopharmaceutical Co. Ltd. Rna molecules and compositions for cancer immunotherapy
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN117919200B (zh) * 2024-01-19 2025-09-05 晟迪生物医药(苏州)有限公司 含有可电离脂质的肺部递送系统、其制备方法和应用
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025194120A1 (en) * 2024-03-14 2025-09-18 Massachusetts Institute Of Technology Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
US12492420B2 (en) 2024-03-29 2025-12-09 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025229572A1 (en) 2024-05-01 2025-11-06 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026015882A1 (en) 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods

Family Cites Families (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2647121A (en) 1951-02-02 1953-07-28 Ruth P Jacoby Diamine-bis-acetamides
US2819718A (en) 1953-07-16 1958-01-14 Isidore H Goldman Drainage tube
US2717909A (en) 1953-09-24 1955-09-13 Monsanto Chemicals Hydroxyethyl-keryl-alkylene-ammonium compounds
US2844629A (en) 1956-04-25 1958-07-22 American Home Prod Fatty acid amides and derivatives thereof
US3096560A (en) 1958-11-21 1963-07-09 William J Liebig Process for synthetic vascular implants
GB1072118A (en) 1962-12-01 1967-06-14 Sandoz Ag Amides of aminopropionic acid
FR1378382A (fr) 1962-12-01 1964-11-13 Sandoz Sa Amides de l'acide amino-propionique, utilisables en particulier pour le traitement des fibres textiles
JPS5141663B1 (es) 1966-03-12 1976-11-11
JPS4822365B1 (es) 1968-10-25 1973-07-05
NL143127B (nl) 1969-02-04 1974-09-16 Rhone Poulenc Sa Versterkingsorgaan voor een defecte hartklep.
US3614954A (en) 1970-02-09 1971-10-26 Medtronic Inc Electronic standby defibrillator
US3614955A (en) 1970-02-09 1971-10-26 Medtronic Inc Standby defibrillator and method of operation
JPS5024216B1 (es) 1970-12-29 1975-08-14
JPS5012146Y2 (es) 1971-07-27 1975-04-15
US3945052A (en) 1972-05-01 1976-03-23 Meadox Medicals, Inc. Synthetic vascular graft and method for manufacturing the same
US3805301A (en) 1972-07-28 1974-04-23 Meadox Medicals Inc Tubular grafts having indicia thereon
JPS49127908A (es) 1973-04-20 1974-12-07
JPS5624664B2 (es) 1973-06-28 1981-06-08
US4013507A (en) 1973-09-18 1977-03-22 California Institute Of Technology Ionene polymers for selectively inhibiting the vitro growth of malignant cells
JPS5123537A (ja) 1974-04-26 1976-02-25 Adeka Argus Chemical Co Ltd Kasozaisoseibutsu
GB1527592A (en) 1974-08-05 1978-10-04 Ici Ltd Wound dressing
US3995623A (en) 1974-12-23 1976-12-07 American Hospital Supply Corporation Multipurpose flow-directed catheter
JPS5813576B2 (ja) 1974-12-27 1983-03-14 アデカ ア−ガスカガク カブシキガイシヤ 安定化された合成高分子組成物
DE2520814A1 (de) 1975-05-09 1976-11-18 Bayer Ag Lichtstabilisierung von polyurethanen
US4281669A (en) 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
JPS5210847A (en) 1975-07-16 1977-01-27 Nippon Steel Corp Pinch roll
US4096860A (en) 1975-10-08 1978-06-27 Mclaughlin William F Dual flow encatheter
CA1069652A (en) 1976-01-09 1980-01-15 Alain F. Carpentier Supported bioprosthetic heart valve with compliant orifice ring
US4134402A (en) 1976-02-11 1979-01-16 Mahurkar Sakharam D Double lumen hemodialysis catheter
US4072146A (en) 1976-09-08 1978-02-07 Howes Randolph M Venous catheter device
US4335723A (en) 1976-11-26 1982-06-22 The Kendall Company Catheter having inflatable retention means
US4099528A (en) 1977-02-17 1978-07-11 Sorenson Research Co., Inc. Double lumen cannula
US4140126A (en) 1977-02-18 1979-02-20 Choudhury M Hasan Method for performing aneurysm repair
US4265745A (en) 1977-05-25 1981-05-05 Teijin Limited Permselective membrane
US4182833A (en) 1977-12-07 1980-01-08 Celanese Polymer Specialties Company Cationic epoxide-amine reaction products
US4180068A (en) 1978-04-13 1979-12-25 Motion Control, Incorporated Bi-directional flow catheter with retractable trocar/valve structure
DE2960875D1 (en) 1978-04-19 1981-12-10 Ici Plc A method of preparing a tubular product by electrostatic spinning
US4284459A (en) 1978-07-03 1981-08-18 The Kendall Company Method for making a molded catheter
US4227533A (en) 1978-11-03 1980-10-14 Bristol-Myers Company Flushable urinary catheter
US4375817A (en) 1979-07-19 1983-03-08 Medtronic, Inc. Implantable cardioverter
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3010841A1 (de) 1980-03-21 1981-10-08 Ulrich Dr.med. 6936 Haag Uthmann Katheder
US4308085A (en) 1980-07-28 1981-12-29 Jenoptik Jena Gmbh Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4339369A (en) 1981-04-23 1982-07-13 Celanese Corporation Cationic epoxide-amine reaction products
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4406656A (en) 1981-06-01 1983-09-27 Brack Gillium Hattler Venous catheter having collapsible multi-lumens
US4475972A (en) 1981-10-01 1984-10-09 Ontario Research Foundation Implantable material
US4401472A (en) 1982-02-26 1983-08-30 Martin Marietta Corporation Hydraulic cement mixes and processes for improving hydraulic cement mixes
US4568329A (en) 1982-03-08 1986-02-04 Mahurkar Sakharam D Double lumen catheter
US4546499A (en) 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
US4530113A (en) 1983-05-20 1985-07-23 Intervascular, Inc. Vascular grafts with cross-weave patterns
US4647416A (en) 1983-08-03 1987-03-03 Shiley Incorporated Method of preparing a vascular graft prosthesis
US4550447A (en) 1983-08-03 1985-11-05 Shiley Incorporated Vascular graft prosthesis
US5104399A (en) 1986-12-10 1992-04-14 Endovascular Technologies, Inc. Artificial graft and implantation method
US4571241A (en) 1983-12-16 1986-02-18 Christopher T Graham Urinary catheter with collapsible urethral tube
US4710169A (en) 1983-12-16 1987-12-01 Christopher T Graham Urinary catheter with collapsible urethral tube
US4737518A (en) 1984-04-03 1988-04-12 Takeda Chemical Industries, Ltd. Lipid derivatives, their production and use
US4562596A (en) 1984-04-25 1986-01-07 Elliot Kornberg Aortic graft, device and method for performing an intraluminal abdominal aortic aneurysm repair
US4782836A (en) 1984-05-24 1988-11-08 Intermedics, Inc. Rate adaptive cardiac pacemaker responsive to patient activity and temperature
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4662382A (en) 1985-01-16 1987-05-05 Intermedics, Inc. Pacemaker lead with enhanced sensitivity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4860751A (en) 1985-02-04 1989-08-29 Cordis Corporation Activity sensor for pacemaker control
CA1320724C (en) 1985-07-19 1993-07-27 Koichi Kanehira Terpene amino alcohols and medicinal uses thereof
US4701162A (en) 1985-09-24 1987-10-20 The Kendall Company Foley catheter assembly
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
DE3616824A1 (de) 1986-05-17 1987-11-19 Schering Ag Verwendung von haertbaren kunstharzmischungen fuer oberflaechenbeschichtungen und druckfarben und verfahren zu ihrer herstellung
EP0255899B1 (de) 1986-07-31 1992-07-15 Werner Prof. Dr.-Ing. Irnich Frequenzadaptierender Herzschrittmacher
US4960409A (en) 1986-09-11 1990-10-02 Catalano Marc L Method of using bilumen peripheral venous catheter with adapter
JPH0829776B2 (ja) 1986-10-29 1996-03-27 東燃化学株式会社 合成樹脂製容器及びその製造用金型
US4720517A (en) 1986-11-24 1988-01-19 Ciba-Geigy Corporation Compositions stabilized with N-hydroxyiminodiacetic and dipropionic acids and esters thereof
DE3728917A1 (de) 1987-08-29 1989-03-09 Roth Hermann J Neue lipide mit unsymmetrisch substituierter disulfidbruecke
US5047540A (en) 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
US4892540A (en) 1988-04-21 1990-01-09 Sorin Biomedica S.P.A. Two-leaflet prosthetic heart valve
US5176661A (en) 1988-09-06 1993-01-05 Advanced Cardiovascular Systems, Inc. Composite vascular catheter
US5024671A (en) 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft
US5200395A (en) 1988-10-18 1993-04-06 Ajinomoto Company, Inc. Pharmaceutical composition of BUF-5 for treating anemia
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5101824A (en) 1990-04-16 1992-04-07 Siemens-Pacesetter, Inc. Rate-responsive pacemaker with circuitry for processing multiple sensor inputs
EP0549590A1 (en) 1990-07-26 1993-07-07 LANE, Rodney James Self expanding vascular endoprosthesis for aneurysms
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
ES2085435T3 (es) 1990-10-09 1996-06-01 Cook Inc Dispositivo dilatador percutaneo.
EP0491082B1 (de) 1990-12-19 1995-04-12 Peter Dr. Ing. Osypka Herzschrittmacherleitung mit einem inneren Kanal und mit einem Elektrodenkopf
US5116360A (en) 1990-12-27 1992-05-26 Corvita Corporation Mesh composite graft
US5405363A (en) 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5545449A (en) 1991-10-02 1996-08-13 Weyerhaeuser Company Polyether-reinforced fiber-based materials
US5151105A (en) 1991-10-07 1992-09-29 Kwan Gett Clifford Collapsible vessel sleeve implant
US5284491A (en) 1992-02-27 1994-02-08 Medtronic, Inc. Cardiac pacemaker with hysteresis behavior
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
WO1994003598A1 (fr) 1992-08-04 1994-02-17 The Green Cross Corporation Agent antiallergique
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5461223A (en) 1992-10-09 1995-10-24 Eastman Kodak Company Bar code detecting circuitry
US5300022A (en) 1992-11-12 1994-04-05 Martin Klapper Urinary catheter and bladder irrigation system
US5496362A (en) 1992-11-24 1996-03-05 Cardiac Pacemakers, Inc. Implantable conformal coil patch electrode with multiple conductive elements for cardioversion and defibrillation
US5716395A (en) 1992-12-11 1998-02-10 W.L. Gore & Associates, Inc. Prosthetic vascular graft
DE69422163T2 (de) 1993-02-19 2000-06-15 Nippon Shinyaku Co., Ltd. Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5697953A (en) 1993-03-13 1997-12-16 Angeion Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5624976A (en) 1994-03-25 1997-04-29 Dentsply Gmbh Dental filling composition and method
US5314430A (en) 1993-06-24 1994-05-24 Medtronic, Inc. Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use
DE4325848A1 (de) 1993-07-31 1995-02-02 Basf Ag Verfahren zur Herstellung von N-(2-Hydroxyethyl)-piperazin
EP0647462A1 (en) 1993-10-06 1995-04-12 The Kansai Electric Power Co., Inc. Method for removing carbon dioxide from combustion exhaust gas
US5609624A (en) 1993-10-08 1997-03-11 Impra, Inc. Reinforced vascular graft and method of making same
SE9303481L (sv) 1993-10-22 1995-04-23 Berol Nobel Ab Hygienkomposition
WO1995013033A1 (en) 1993-11-08 1995-05-18 Lazarus Harrison M Intraluminal vascular graft and method
KR960705798A (ko) 1993-11-24 1996-11-08 벤자민 에프 맥그로우 피페라진의 양쪽친화성 유도체(amphiphilic derivatives of piperazine)
US5464924A (en) 1994-01-07 1995-11-07 The Dow Chemical Company Flexible poly(amino ethers) for barrier packaging
US5833979A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5965434A (en) 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
EP0822835A1 (en) 1995-04-17 1998-02-11 Imarx Pharmaceutical Corp. Hybrid magnetic resonance contrast agents
US5772694A (en) 1995-05-16 1998-06-30 Medical Carbon Research Institute L.L.C. Prosthetic heart valve with improved blood flow
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5607385A (en) 1995-08-17 1997-03-04 Medtronic, Inc. Device and algorithm for a combined cardiomyostimulator and a cardiac pacer-carioverter-defibrillator
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
FR2740978B1 (fr) 1995-11-10 1998-01-02 Ela Medical Sa Dispositif medical actif du type defibrillateur/cardioverteur implantable
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5913848A (en) 1996-06-06 1999-06-22 Luther Medical Products, Inc. Hard tip over-the-needle catheter and method of manufacturing the same
US5736573A (en) 1996-07-31 1998-04-07 Galat; Alexander Lipid and water soluble derivatives of drugs
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
JPH10129797A (ja) 1996-10-25 1998-05-19 Toshiba Mach Co Ltd 生ビール注出弁及び注出ノズルからの泡の排出方法
US6887665B2 (en) 1996-11-14 2005-05-03 Affymetrix, Inc. Methods of array synthesis
US6204297B1 (en) 1996-11-26 2001-03-20 Rhodia Inc. Nonionic gemini surfactants
JPH10197978A (ja) 1997-01-09 1998-07-31 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5945326A (en) 1997-03-20 1999-08-31 New England Biolabs, Inc. Method for cloning and producing the Spel restriction endonuclease
JPH115786A (ja) 1997-06-13 1999-01-12 Pola Chem Ind Inc 新規アミノヒドロキシプロピルピペラジン誘導体
US6067471A (en) 1998-08-07 2000-05-23 Cardiac Pacemakers, Inc. Atrial and ventricular implantable cardioverter-defibrillator and lead system
JPH1180142A (ja) 1997-09-05 1999-03-26 Pola Chem Ind Inc ジフェニルアルキル化合物の製造法
AU9319398A (en) * 1997-09-19 1999-04-05 Sequitur, Inc. Sense mrna therapy
US6096075A (en) 1998-01-22 2000-08-01 Medical Carbon Research Institute, Llc Prosthetic heart valve
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6176877B1 (en) 1998-04-20 2001-01-23 St. Jude Medical, Inc. Two piece prosthetic heart valve
DE19822602A1 (de) 1998-05-20 1999-11-25 Goldschmidt Ag Th Verfahren zur Herstellung von Polyaminosäureestern durch Veresterung von sauren Polyaminosäuren oder Umesterung von Polyaminosäureestern
NO313244B1 (no) 1998-07-08 2002-09-02 Crew Dev Corp Fremgangsmåte for isolering og produksjon av magnesitt eller magnesiumklorid
US6055454A (en) 1998-07-27 2000-04-25 Cardiac Pacemakers, Inc. Cardiac pacemaker with automatic response optimization of a physiologic sensor based on a second sensor
WO2000010622A1 (en) 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US6379698B1 (en) 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
CA2369595C (en) 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US6169923B1 (en) 1999-04-23 2001-01-02 Pacesetter, Inc. Implantable cardioverter-defibrillator with automatic arrhythmia detection criteria adjustment
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
AU6105300A (en) 1999-07-16 2001-02-05 Purdue Research Foundation Vinyl ether lipids with cleavable hydrophilic headgroups
DE19937275C2 (de) 1999-08-06 2003-10-30 Framatome Anp Gmbh Verfahren und Datenverarbeitungsprogramm zur Ermittlung einer Kenngröße eines Nuklearreaktors
US6358278B1 (en) 1999-09-24 2002-03-19 St. Jude Medical, Inc. Heart valve prosthesis with rotatable cuff
US6371983B1 (en) 1999-10-04 2002-04-16 Ernest Lane Bioprosthetic heart valve
CA2395636A1 (en) 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
US6370434B1 (en) 2000-02-28 2002-04-09 Cardiac Pacemakers, Inc. Cardiac lead and method for lead implantation
US6565960B2 (en) 2000-06-01 2003-05-20 Shriners Hospital Of Children Polymer composite compositions
WO2002000870A2 (en) 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
IL138474A0 (en) 2000-09-14 2001-10-31 Epox Ltd Highly branched water-soluble polyamine oligomers, process for their preparation and applications thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20020094528A1 (en) 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
JP2002167368A (ja) 2000-12-01 2002-06-11 Nitto Denko Corp アルキル置換デンドリマーおよびその製造法
US20020192721A1 (en) 2001-03-28 2002-12-19 Engeneos, Inc. Modular molecular clasps and uses thereof
TW588032B (en) 2001-04-23 2004-05-21 Shinetsu Chemical Co New tertiary amine compound having ester structure and method for producing the same
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
CA2466328A1 (en) 2001-11-09 2003-05-15 Bayer Healthcare Ag Isotopically coded affinity markers 3
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7601367B2 (en) 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
US20040028804A1 (en) 2002-08-07 2004-02-12 Anderson Daniel G. Production of polymeric microarrays
AU2003260724A1 (en) 2002-08-22 2004-03-11 Celltran Limited Cell culture surface
CA2504910A1 (en) 2002-11-04 2004-05-21 Ge Bayer Silicones Gmbh & Co. Kg Linear polyamino and/or polyammonium polysiloxane copolymers i
CA2506843A1 (en) 2002-11-22 2004-06-10 Novo-Nordisk A/S 2,5-diketopiperazines for the treatment of obesity
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7619017B2 (en) 2003-05-19 2009-11-17 Wacker Chemical Corporation Polymer emulsions resistant to biodeterioration
EP1644479A4 (en) 2003-06-16 2008-04-23 Mark W Grinstaff MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION
EP1675943A4 (en) 2003-09-15 2007-12-05 Massachusetts Inst Technology SYNTHESIS OF BIOMATERIALS ARRANGED IN AN ARRAY IN THE NANOLITE ASSEMBLY AND SCREENING THEREOF
AU2004272646B2 (en) 2003-09-15 2011-11-24 Arbutus Biopharma Corporation Polyethyleneglycol-modified lipid compounds and uses thereof
US20050069590A1 (en) 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
EP1683784A4 (en) 2003-11-10 2007-08-22 Nippon Kayaku Kk DIIMONIUM SALT CONNECTION AND ITS USE
US7022214B2 (en) 2004-01-21 2006-04-04 Bio-Rad Laboratories, Inc. Carrier ampholytes of high pH range
US7556684B2 (en) 2004-02-26 2009-07-07 Construction Research & Technology Gmbh Amine containing strength improvement admixture
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
CN1981044B (zh) * 2004-06-07 2010-05-05 普洛体维生物治疗公司 包封干扰rna的脂质
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
DE102004043342A1 (de) 2004-09-08 2006-03-09 Bayer Materialscience Ag Blockierte Polyurethan-Prepolymere als Klebstoffe
GB0502482D0 (en) 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
EP1869106B1 (en) 2005-03-28 2014-06-25 Dendritic Nanotechnologies, Inc. Janus dendrimers and dendrons
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
EP4174179B1 (en) * 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US20090221684A1 (en) 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
CN100569877C (zh) 2005-12-30 2009-12-16 财团法人工业技术研究院 含多uv交联反应基的分枝状结构化合物及其应用
US20070275923A1 (en) 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
ES2293834B1 (es) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
CA2658768C (en) 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
CN105030654A (zh) 2006-10-03 2015-11-11 阿尔尼拉姆医药品有限公司 含脂质的制品
EP2139461A2 (en) 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
JP5186126B2 (ja) 2007-03-29 2013-04-17 公益財団法人地球環境産業技術研究機構 新規トリアジン誘導体ならびにその製法およびそのガス分離膜としての用途
WO2008137470A1 (en) 2007-05-01 2008-11-13 Pgr-Solutions Multi-chain lipophilic polyamines
WO2009046220A2 (en) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
CA3044980A1 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
JP5024216B2 (ja) 2008-07-23 2012-09-12 トヨタ自動車株式会社 内燃機関の点火時期制御装置及び点火時期制御方法
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN104382853A (zh) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
WO2010062322A2 (en) 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
MX351819B (es) 2008-11-10 2017-10-30 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
EP2350296A4 (en) * 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS
EP2405921A4 (en) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION
US20100222489A1 (en) 2009-02-27 2010-09-02 Jiang Dayue D Copolymer composition, membrane article, and methods thereof
CN102334237B (zh) 2009-04-02 2015-05-13 西蒙公司 电信接线板
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
PT3431076T (pt) 2009-06-10 2021-10-26 Arbutus Biopharma Corp Formulação lipídica melhorada
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
WO2011000108A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
NZ598125A (en) 2009-07-30 2014-05-30 Salvat Lab Sa Apaf-1 inhibitor compounds
CN102695525B (zh) 2009-07-31 2016-01-20 埃泽瑞斯公司 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna
DE102009043342A1 (de) 2009-09-29 2011-03-31 Bayer Technology Services Gmbh Stoffe für selbstorganisierte Träger zur kontrollierten Freisetzung eines Wirkstoffs
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
BR112012015755B1 (pt) 2009-12-23 2021-06-22 Novartis Ag Lipídeo furtivo, e composição
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
CN101863544B (zh) 2010-06-29 2011-09-28 湖南科技大学 一种氰尿酸基重金属螯合絮凝剂及其制备方法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012133737A1 (ja) 2011-03-31 2012-10-04 公益財団法人地球環境産業技術研究機構 架橋性アミン化合物、該化合物を用いた高分子膜及びその製造方法
BR112013029490A2 (pt) 2011-05-17 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos
EP2532649B1 (en) 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
ES2663360T3 (es) 2011-06-08 2018-04-12 Translate Bio, Inc. Lípidos escindibles
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
KR20140097143A (ko) 2011-10-05 2014-08-06 프로티바 바이오쎄라퓨틱스, 인코포레이티드 알데히드 데히드로게나제를 침묵시키기 위한 조성물 및 방법
CN113149869A (zh) 2011-10-27 2021-07-23 麻省理工学院 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物
WO2013130161A1 (en) 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
WO2013090186A1 (en) 2011-12-14 2013-06-20 modeRNA Therapeutics Modified nucleic acids, and acute care uses thereof
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US20130165504A1 (en) 2011-12-21 2013-06-27 modeRNA Therapeutics Methods of increasing the viability or longevity of an organ or organ explant
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
CN110003030A (zh) 2012-02-24 2019-07-12 野草莓树生物制药公司 三烷基阳离子脂质及其使用方法
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20150050354A1 (en) 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US20140275229A1 (en) 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
EP2931914A4 (en) 2012-12-13 2016-08-17 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR CHANGING THE CELL PHENOTYPE
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20160022774A1 (en) 2013-03-12 2016-01-28 Moderna Therapeutics, Inc. Diagnosis and treatment of fibrosis
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR102248744B1 (ko) * 2013-03-14 2021-05-06 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
PT2970456T (pt) 2013-03-14 2021-08-06 Translate Bio Inc Métodos e composições para a administração de anticorpos codificados por marn
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014210356A1 (en) 2013-06-26 2014-12-31 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
EP3971287A1 (en) 2013-07-11 2022-03-23 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3033325B1 (en) 2013-07-23 2019-12-04 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3058082A4 (en) 2013-10-18 2017-04-26 ModernaTX, Inc. Compositions and methods for tolerizing cellular systems
MX381303B (es) * 2013-10-22 2025-03-12 Shire Human Genetic Therapies Composición que comprende un ácido ribonucleico mensajero que codifica argininosuccinato sintetasa para usarse en el tratamiento de la deficiencia de argininosuccinato sintetasa.
WO2015061467A1 (en) * 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
JP6506749B2 (ja) * 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのｍＲＮＡ療法
KR102387898B1 (ko) * 2014-06-24 2022-04-15 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
CN107208095B (zh) 2014-10-02 2021-11-16 阿布特斯生物制药公司 用于使乙型肝炎病毒基因表达沉默的组合物和方法
WO2016071857A1 (en) 2014-11-07 2016-05-12 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus expression
WO2016077123A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Multiparametric nucleic acid optimization
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
EP3226912B1 (en) * 2014-12-05 2021-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of articular disease
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US11167043B2 (en) * 2017-12-20 2021-11-09 Translate Bio, Inc. Composition and methods for treatment of ornithine transcarbamylase deficiency
BR112020021054A2 (pt) 2018-04-25 2021-02-17 Ethris Gmbh composição, processo para a preparação de uma composição, e, composições sólida e para uso
US20200016274A1 (en) * 2018-05-30 2020-01-16 Translate Bio, Inc. Messenger rna vaccines and uses thereof

Also Published As

Publication number Publication date
US20220347099A1 (en) 2022-11-03
CN105813656A (zh) 2016-07-27
CN105813656B (zh) 2021-01-15
EP3060257A1 (en) 2016-08-31
JP2022081663A (ja) 2022-05-31
JP2021091729A (ja) 2021-06-17
JP7546835B2 (ja) 2024-09-09
EP3871696A1 (en) 2021-09-01
AU2021200980A1 (en) 2021-03-11
JP2019073557A (ja) 2019-05-16
US20150140070A1 (en) 2015-05-21
US20170281542A1 (en) 2017-10-05
KR101988552B1 (ko) 2019-09-25
EP3871696B1 (en) 2025-03-19
JP6646773B2 (ja) 2020-02-14
AU2023206132A1 (en) 2023-09-28
ES3032935T3 (en) 2025-07-29
CN112656954A (zh) 2021-04-16
CN112618732A (zh) 2021-04-09
IL245030A0 (en) 2016-05-31
US10052284B2 (en) 2018-08-21
SG11201602943PA (en) 2016-05-30
US20240293319A1 (en) 2024-09-05
AU2019200474A1 (en) 2019-02-14
AU2021200980B2 (en) 2023-04-20
EP3871696C0 (en) 2025-03-19
CA2928078A1 (en) 2015-04-30
US11890377B2 (en) 2024-02-06
AU2014340155B2 (en) 2018-11-01
ES2865699T3 (es) 2021-10-15
JP2023169139A (ja) 2023-11-29
JP7392212B2 (ja) 2023-12-06
AU2019200474B2 (en) 2020-11-26
JP6525435B2 (ja) 2019-06-12
KR20190067261A (ko) 2019-06-14
JP7046246B2 (ja) 2022-04-01
US20200078299A1 (en) 2020-03-12
CL2016000957A1 (es) 2016-12-09
US10493031B2 (en) 2019-12-03
JP2016535738A (ja) 2016-11-17
AU2014340155A1 (en) 2016-05-05
EP3060257B1 (en) 2021-02-24
MX2016005238A (es) 2016-08-12
US9629804B2 (en) 2017-04-25
US20180369144A1 (en) 2018-12-27
EA201690576A1 (ru) 2016-10-31
JP2020073567A (ja) 2020-05-14
WO2015061467A1 (en) 2015-04-30
NZ718817A (en) 2020-07-31
US10959953B2 (en) 2021-03-30
KR102096796B1 (ko) 2020-05-27
BR112016009077A2 (pt) 2017-09-19
JP6851516B2 (ja) 2021-03-31
KR20160091893A (ko) 2016-08-03

Similar Documents

Publication Publication Date Title
PE20161242A1 (es) Formulaciones de lipidos para la administracion de arn mensajero
CY1124499T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
CO2021005774A2 (es) Lípidos con amina ionizables
CO2021014831A2 (es) Lípidos de amina ionizables y nanopartículas lipídicas
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
CO2021008838A2 (es) Lípidos con amina modificados
AR113031A1 (es) Composiciones de nanopartículas lipídicas (lnp) que comprende arn
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
CY1124481T1 (el) Σταθερα χωρις συντηρητικα μυδριατικα και αντιοξειδωτικα διαλυματα για εγχυση
BR112014013175A2 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
MX392239B (es) Emulsiones catiónicas de agua en aceite.
MX2012000389A (es) Imidazoles fusionados y composiciones que los comprenden para el tratamiento de enfermedades parasitarias, tales como, por ejemplo, malaria.
AR094195A1 (es) Enjuagues bucales de haluros de zinc aminoacidos
MX2016004605A (es) Formulaciones de anticuerpos estables acuosas.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
UY33643A (es) ?Conjugado cristalino de naloxol-PEG?.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
MX2021001441A (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal